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Abstract
RATIONALE—Pulmonary complications after hematopoietic stem cell transplant (SCT) are 
associated with increased mortality. Genetic markers for those at risk for pulmonary impairment 
post-SCT have not been widely investigated.
METHODS—Forty-nine patients were retrospectively selected from a single institution’s 
biorepository with linked clinical data. All subjects performed pre-SCT PFTs. Genotyping was 
conducted using the Infinium Exome-24 BeadChip. Four single nucleotide polymorphisms (SNPs) 
were selected (rs1800871, rs1695, rs1800629, rs12477314) and evaluated for association with PFT 
parameters as change over time from baseline. Associations between SNPs and PFT parameters 
were assessed and adjusted for the following confounding variables: age, gender, and race.
RESULTS—Using the recessive genetic model, patients with one or two minor alleles for the 
glutathione S-transferase P1 (GSTP1) SNP rs1695 had a lower decline in FEV1 and FEF25–75 at 
one-year post-SCT compared to patients who were homozygous for the ancestral allele (adjusted 
p-values <0.01 and 0.02, respectively). No other SNPs were significantly associated with other 
PFT parameters.
CONCLUSIONS—Our findings suggest that GSTP1 genotype may be associated with lung 
function during the first year post-SCT. Identifying and investigating genes that predispose 
patients to pulmonary complications after SCT may allow for more personalized patient 
management based on pre-emptive genetic testing. The glutathione S-transferase gene merits 
further investigation.
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Introduction
Hematopoietic stem cell transplantation (SCT) has been increasingly used in pediatric 
patients to treat both malignant and non-malignant diseases. Advances in supportive care 
and techniques that prevent complications of SCT have allowed for treatment of a wider 
variety of diseases with improved outcomes. For supportive care, we have expanded our use 
of prophylactic antimicrobial therapy in this population. More targeted approaches to 
therapy, including decreased use of total body irradiation, have been implemented. 
Furthermore, improved skills in the care of critically ill pediatric patients have increased 
patient post-SCT survival. Regardless of these advances, pulmonary complications after 
SCT commonly occur and are a significant source of post-SCT morbidity and mortality.
Pulmonary complications after SCT have been estimated to occur in 40–60% of patients in 
adult studies, which can be separated into infectious and noninfectious etiologies (1). In a 
recent pediatric study, noninfectious pulmonary complications were reported to occur in 
28% of patients, and survival at 10 years was 76% in patients without early pulmonary 
complications in comparison to 18% in patients with early pulmonary complications (2). 
Early complications were defined as those occurring within the first 100 days post-SCT. The 
predominant pulmonary complication observed was idiopathic pneumonia syndrome (IPS). 
Pleural effusion, pulmonary hemorrhage, reactive airway disease, bronchiectasis, and 
bronchiolitis obliterans were other noted pulmonary complications after SCT.
Furthermore, lung function abnormalities noted on pulmonary function tests (PFTs) have 
been documented in patients after SCT. Decreased diffusion capacity is the most common 
abnormality identified, followed by restriction. Diffusion and restrictive impairments have 
been reported to improve with time (3). Restriction often occurs with IPS and has been 
linked to acute graft-versus-host disease (GVHD) (4). Bronchiolitis obliterans, the most 
concerning pulmonary complication, causes progressive pulmonary compromise. 
Obstructive impairment as noted in bronchiolitis obliterans has been linked to chronic 
GVHD.
Previous studies have attempted to create models that predict pulmonary outcomes after 
SCT based on pre-SCT PFTs. A large adult study in 2005 demonstrated that a decrease in all 
lung function parameters pre-SCT was associated with a stepwise increase of developing 
early respiratory failure and death post-SCT (5). This study also constructed a “Lung 
Function Score” (LFS), which correlated well with risk of early respiratory failure and 
death. The score was calculated using forced expiratory volume in one second (FEV1) and 
diffusing capacity (DLCO). In 2010, a similar study was completed in a smaller cohort of 
pediatric patients, and the LFS was validated in this population (6). In spite of studies such 
as these, no scoring system for pulmonary risk is universally used in SCT patients prior to 
transplant.
Given the impact of pulmonary complications on survival, identifying patients who are at 
risk has the potential to impact prognosis and improve patient outcomes. However, using 
PFT data alone to predict post-SCT pulmonary complications provides only general 
knowledge of those who are at risk for pulmonary complications post-transplant. 
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Increasingly, the desire for personalized medicine has driven evaluation of genetic variation 
in predicting disease outcomes. Differences in single nucleotide polymorphism (SNPs) have 
been investigated as modulators of common pulmonary diseases such as asthma (7, 8). Our 
objective was to compare lung function indices over time to four selected SNPs previously 
reported to be associated with lung disease after SCT or etiologies leading to restrictive 
and/or obstructive pulmonary impairment. The overall goal of this study was to identify 
SNPs, and their corresponding genes, that may be associated with pulmonary complications 
after SCT. We hypothesized that genes related to obstructive and restrictive changes in other 
underlying lung disease etiologies would be associated with similar impairment in PFTs 
after SCT.
Materials and Methods
Patients who underwent SCT from 2004 to 2010 at Riley Children’s Hospital were 
retrospectively selected for analysis (Indianapolis, IN) (Table 1). A total of 98 patients who 
underwent SCT were included in the study cohort. Three patients were excluded who 
underwent autologous SCT. Of the remaining 95 patients, 62 completed PFTs prior to SCT 
(65%). Of these 62, 49 had samples available for exon SNP genotyping, which was 
completed using a PCR-based assay.
The Infinium Exome-24 BeadChip was used to analyze SNPs of functional exonic variants 
from patient exomes. The BeadChip consists of greater than 240,000 markers that represent 
European, African American, Chinese, and Hispanic populations. DNA samples from the 
subjects were obtained from left over clinical samples in the medical genetics laboratory, for 
which consent had been previously obtained for storage and further analysis. DNA was 
extracted from whole blood using the Qiagen DNA Blood Mini Kit and quantified using 
Fisher Scientific’s Quant-iT BR dsDNA reagent kit with the Quant-iT fluorometer. All 
samples were collected prior to SCT such that no donor DNA was represented in the 
samples. The Indiana Retrospective HSCT Biobank as well as this sample and data 
utilization project were reviewed and approved by the Indiana University School of 
Medicine Institutional Review Board (IRB).
Lung function tests were performed based on American Thoracic Society/European 
Respiratory Society criteria. Spirometry, plethysmography and diffusing capacity were 
evaluated for all 49 patients. All parameters were assessed as a change from baseline, with 
the baseline being the PFTs obtained prior to SCT. Changes in FEV1, FEV1/FVC (forced 
vital capacity), and forced expiratory flows between 25% and 75% of forced vital capacity 
(FEF25–75) were assessed. Total lung capacity (TLC) was used to identify restrictive change. 
Diffusion capacity was adjusted for hemoglobin (DLco). All PFTs were normalized for age, 
gender, weight, and height using z-scores.
Available follow up PFTs were collected for the 49 patients. Baseline, or pre-SCT, PFTs 
were obtained an average of one month, but no more than two months, prior to SCT. 
Seventeen patients died or were otherwise unable to complete follow-up PFTs. Thirty-one 
patients completed post-SCT PFTs at one year; one patient did not complete PFTs until two 
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years post-SCT. Follow up PFTs at two, three, four, and five years were also recorded, but 
were less consistently performed.
Based on a review of the current literature using Ovid, four SNPs were selected within the 
exomes of four distinct genes: rs1800629 (tumor necrosis factor α, or TNFα), rs1800871 
(interleukin 10, or IL-10), rs1695 (glutathione-s-transferase P1, or GSTP1), and rs12477314 
(Histone deacetylase 4, or HDAC4). Key phrases searched in the Ovid were “single 
nucleotide polymorphism,” with either “pulmonary restriction” or “pulmonary obstruction.” 
Articles that described specific SNPs in the exome were used. These SNPs were selected 
because they have been implicated in modifying severity of lung diseases which cause 
restriction and obstruction such as asthma and α1-antitrypsin deficiency (7, 8, 9). Each SNP 
has a known “ancestral allele,” referred to as the “wild type” in animal models, which is the 
more common nucleotide found in the population. There is also a documented variant allele, 
which we refer to as the “minor allele.”
Once SNPs were selected, each SNP was analyzed with three different models to ensure that 
the different combinations were all tested: a dominant model, a recessive model, and an 
additive model. In the dominant model, the group of individuals with two minor alleles was 
compared to a group of subjects having one or two of the ancestral alleles, considered the 
dominant group. In the recessive model, individuals with one or both minor alleles were 
grouped together, considered the recessive group, and compared to those having only 
ancestral alleles. In the additive model the number of minor alleles were treated as an ordinal 
outcome, with participants being categorized as having 0, 1, or 2 minor alleles.
ANOVA models were used to evaluate for associations between each SNP model and PFT 
outcomes as change from baseline to each follow-up time point. ANCOVA models were 
used to adjust for possible confounding variables: age, gender, and race. All analytic 
assumptions were verified and all analyses were performed using SAS v9.4 (SAS Institute, 
Cary, NC). Repeated measures analyses were not performed, due to low sample sizes at the 
later follow-up periods. P values were corrected for multiple comparisons. Since four SNPs 
were assessed, the standard P-value of 0.05, which normally designates significance, was 
adjusted to 0.0125. Z-scores for spirometry were calculated with the SAS GLI macro, using 
the Global Lungs Initiative algorithms (10, 11). Z-scores for DLco and TLC were calculated 
using published references standards (12, 13, 14).
Results
Using the recessive genetic model, patients who were homozygous for the ancestral allele of 
the glutathione-S-transferase P1 (GSTP1) SNP (rs1695) had a larger decline in FEV1 
(adjusted p-value < 0.01) and FEF25–75 (adjusted p-value = 0.02) values at one-year post-
SCT compared to patients with one or two minor alleles (Figure 1). This association was not 
significant in subsequent post-SCT years. Using the adjusted P-value of 0.0125 for 
significance, FEF25–75 becomes narrowly outside the area of significance using the recessive 
model. FEV1 remains significant. No other SNPs were significant on statistical analysis in 
comparison with other PFT parameters (Table 2).
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Death was divided into death from primary disease and transplant-related mortality. Neither 
death overall nor transplant-related mortality were significantly associated with any of the 
SNPs using any genetic model. Of the patients included in this study cohort who died, the 
average time to death post-SCT was approximately one year (380 days).
Discussion
We report that patients who were homozygous for the ancestral allele of the GTSP1 SNP 
rs1695 had a greater decline in lung function at one year after SCT compared to those who 
had at least one minor allele of the GTSP1 SNP rs1695. Specifically, FEV1 significantly 
declined and there was evidence of airflow limitation with diminished FEF25–75 values at 
one-year post-SCT in those homozygous for the ancestral allele of the GTSP1 SNP rs1695. 
Though FVC and TLC decreased post-transplant, the change was not significantly 
associated with the four identified SNPs. Given this, the decline in FEV1 and FEF25–75 in 
those homozygous for the ancestral allele of the GTSP1 SNP rs1695 is more indicative of an 
obstructive pattern than a restrictive one. Airway obstruction is one of the more concerning 
findings on spirometry because these findings are often associated with bronchiolitis 
obliterans.
The association between FEV1 and GSTP1 was not demonstrated on the PFTs in subsequent 
years post-SCT. There are a couple of possible explanations. Unfortunately, follow up after a 
year was limited in our patient population leading to a smaller sample size for those that 
completed PFTs at two, three, four, and five years. The data may have been skewed by this 
smaller sample size. It is also known, however, that pulmonary function in general improves 
with time after SCT in patients who survive early complications. A retrospective study 
performed at Riley Hospital for Children in 2012 demonstrated a decline in PFTs (FEV1 and 
TLC) 1-year post-SCT, which largely recovered at 2 years post-SCT (15).
The four SNPs selected for this study were chosen because of previous reports 
demonstrating that they mediate severity of pulmonary disease after SCT or in other 
underlying etiologies known to cause restrictive and obstructive disease, such as asthma and 
α1-antitrypsin deficiency. Each of these follows a common disease pathway, yet there are a 
wide variety of clinical presentations, suggesting variability in other genetic modifiers. From 
the limited literature available in this area, we chose the SNPs within the following genes: 
TNFα, IL-10, HDAC4, and GSTP1.
Previously, TNFα was assessed in a study of cytokine expression in bronchoalveolar lavage 
samples from patients with pulmonary complications after SCT (16). TNFα expression was 
demonstrated to be significantly increased in patients with both infectious and non-
infectious pulmonary complications, and this elevation correlated with a poorer prognosis 
overall. IL-10 was demonstrated to be a genetic modifier for severity of chronic obstructive 
pulmonary disease (COPD) in patients with α1-antitrypsin deficiency (9). Finally, a 
preliminary study revealed that HDAC4 genetic variation may be associated with the 
development of asthma and COPD as patients age (17). Although all three of these genes 
seemed like promising candidates for this study, none were shown to be significantly 
associated with PFT outcomes in our patient population.
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As stated, Glutathione-S-transferase P1 (GSTP1) was significantly associated with lung 
function in our patient population. Glutathione-S-transferase is a superfamily of metabolic 
enzymes involved in the conjugation of reduced glutathione (18). These reactions are 
generally considered detoxifying and protective from cytotoxic agents, but they have also 
been noted to create intermediate metabolites that are more toxic than their precursors (19). 
In addition, these enzymes are known to metabolize chemotherapeutic agents and are often 
over expressed in tumors that are refractory to chemotherapy. GSTP1 is widely found in 
human epithelium, especially the lungs, esophagus, and placenta. GSTP1 is most abundantly 
expressed in the alveoli, alveolar macrophages, and bronchioles and has been studied for its 
role in ameliorating the effects of air pollution, tobacco smoke, and α1-antitrypsin 
deficiency (7, 8, 20).
The SNP that we investigated within the GSTP1 gene is a substitution of adenosine (the 
ancestral allele) for guanine (the minor allele) at position 105. This leads to a missense 
mutation and causes the amino acid isoleucine to be replaced by valine. In a 2004 study in 
Taiwan, patients coding for isoleucine at this site were demonstrated to be at increased risk 
of developing asthma when exposed to air pollution. These findings correlate well with our 
results, demonstrating that the ancestral allele leads to diminished FEV1 values and more 
airflow limitation in SCT patients one year post-transplant. In contrast, a 2006 publication 
reported a higher susceptibility to asthma in children who were exposed to tobacco smoke 
and had the minor allele, which codes for valine, at the 105 position. Though these are 
conflicting reports, they emphasize the importance of GSTP1 in modifying disease severity 
and demonstrate the need for further research into the mechanism of action of GSTP1.
In our study population, there was no correlation identified between GSTP1 and transplant-
related mortality. The average time of death in this study, however, was around one year. 
This correlates chronologically with decrease in FEV1 and FEF25–75 related to GSTP1. 
Given the fact that not all transplant-related mortality was secondary to pulmonary 
complications, it is not surprising that the two are not strongly correlated.
Further investigation of GSTP1 needs to be performed to assess its utility as a biomarker for 
pulmonary complications after SCT. In this study, patients with one or more minor allele for 
GSTP1 had better PFTs one-year post-SCT. One possible mechanism of action for this 
finding is that the minor allele leads to increased function of the GSTP1 gene; thereby, 
providing more protection against cytotoxic agents administered in preparation for and 
during SCT. Murine models have confirmed that the pro-inflammatory state following SCT 
leads to an increased production of reactive oxygen species (21, 22). GSTP1 may be an 
important modulator of these effects after transplant.
Identifying best management approaches that decrease the morbidity and mortality of SCT 
is critical. Previous studies have suggested that depletion of T cells in the transplant itself 
provides protection against GVHD and subsequently, serious pulmonary complications (23). 
This benefit must be weighed against the loss of important graft-versus-leukemia effects as 
well as the associated increased degree of immunosuppression and prolonged time to 
immune reconstitution when T cell depletion is performed. Newer therapies such as 
Alemtuzumab, or Campath, are being implemented to suppress T and B cells after SCT with 
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fewer negative side effects than T cell depletion (24). If GSTP1 genotype is validated as a 
marker for poor pulmonary outcomes, and patients are found to be at risk prior to transplant, 
the management of T and B cells pre-SCT and post-SCT is one of many areas of 
intervention.
Other possible strategies include reducing the intensity of the preparation used for 
transplant. Specifically, treatments known to have significant pulmonary side effects, such as 
busulfan and total body irradiation, could potentially be avoided. Finally, other tactics for 
decreasing pulmonary inflammation such as inhaled corticosteroids could be studied.
This pilot study has several limitations. The initial sample size of patients who underwent 
SCT during the given time period was larger than the selected population. As noted above, 
patients were excluded who did not undergo pre-SCT PFTs and exome SNP array PCR 
analysis. There were 25 patients who were too young to perform baseline PFTs and were 
excluded. Generally, the patients who did not perform baseline PFTS were those who were 
less than 5 years of age. In patients who performed pre-SCT PFTs, follow up at one year 
was excellent unless the patient died or was too sick to perform PFTs.
Our sample size was too small to correct for confounders such as total body irradiation and 
chemotherapy received prior to SCT. In order to ameliorate this issue, each patient’s PFT 
parameters were compared to his or her own personal baseline PFTs just prior to transplant. 
The change from baseline was compared between patients due to the variability in 
pulmonary impairment prior to SCT. However, due to the small sample size, a more 
restrictive change post-SCT in those homozygous for the ancestral allele of the GTSP1 SNP 
rs1695 may not have been fully delineated.
After correcting for multiple comparisons, the association between FEV1 and the GSTP1 
SNP remained significant at one year; however, FEF25–75 did not have a strong enough 
association to retain its significance. A decrease in FEV1 without a significant decreased in 
TLC, coupled with the airflow limitation noted in the FEF25–75 values as seen in our study, 
is suggestive of airway obstruction, one of the more concerning pulmonary complications 
noted after SCT. A mild restrictive change is often seen post-SCT. In our study, patients who 
were homozygous for the ancestral allele of GSTP1 were observed to develop a more 
accelerated decline in FEV1 and FEF25–75 1 year post-SCT.
In comparison to the other three SNPS that were investigated in this study, GSTP1 stood out 
as an excellent candidate for further research in regards to SCT. As we move towards an era 
of personalized medicine in which genetic variation is widely assessed and applied clinically 
to patients, identifying genes becomes increasingly important. GSTP1 certainly merits 
further investigation.
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Figure 1. 
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Table 1
Demographics
Age (years) 12.4 (4.3)
Height (cm) 150.1 (20.7)
Weight (kg) 49.3 (19.2)
Sex
  Male 27 (55%)
  Female 22 (45%)
Ethnicity
  Black 4 (8%)
  Hispanic 2 (4%)
  White 43 (88%)
Reason for SCT
  Malignant disease 37 (75.5)
  Non-malignant disease 12 (24.5)
Baseline FEV1 (z-score) −0.25 (1.4)
Baseline FVC (z-score) −0.36 (1.4)
Baseline FEV1/FVC (z-score) −0.07 (1.2)
Baseline FEF2575 (z-score) −0.25 (1.3)
Baseline DLCO (z-score) −2.57 (2.2)
Baseline TLC (z-score) −2.23 (0.6)
Busulfan 15 (30.6%)
TBI 30 (61.2%)
Values are means (standard deviation) for continuous variables and frequency (percent) for categorical variables.
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